Developer of RNA-based therapies for treating heart diseases. It offers a platform that integrates multimodal functional genomics with computational tools to determine RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs) to inhibit lncRNAs to prevent Fibrosis. Founded in 2017, headquartered in Lausanne, Switzerland. The company has raised $90.0M in funding at the series a stage. The team comprises 68 (Jun 30, 2026) employees. HAYA Therapeutics operates in the Genomics, Cardiac and Vascular Disorders, Gene Therapy, Clinical Genomics sectors. The company focuses on Diversified, Non-Coding RNA, MassCha. Notable investors include Broadview Ventures, Apollo Health Ventures, 4see ventures, Schroders Capital, Viva BioInnovator, BERNINA BioInvest, among others. The company has a team of 68 employees.
HAYA Therapeutics
Series ADeveloper of RNA-based therapies for treating heart diseases. It offers a platform that integrates multimodal functional genomics with computational tools to determine RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs) to inhibit lncRNAs to prevent Fibrosis. Founded in 2017, headquartered in Lausanne, Switzerland. The company has raised $90.0M in funding at the series a stage. The team…
About
Business model
Cardiac and Vascular Disorders > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Transcriptomics > Non-Coding RNA,
MassChallenge Batches > Switzerland > 2017 > Gold
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.